## Ana-Lucia Andrade

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5225162/publications.pdf Version: 2024-02-01

		489802	488211
32	1,419	18	31
papers	citations	h-index	g-index
22			
32	32	32	2555
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The direct effect of pneumococcal conjugate vaccines on invasive pneumococcal disease in children in the Latin American and Caribbean region (SIREVA 2006–17): a multicentre, retrospective observational study. Lancet Infectious Diseases, The, 2021, 21, 405-417.	4.6	24
2	Comparison of static and dynamic models of maternal immunization to prevent infant pertussis in Brazil. Vaccine, 2021, 39, 158-166.	1.7	4
3	Effect of pneumococcal conjugate vaccines on invasive pneumococcal disease – Authors' reply. Lancet Infectious Diseases, The, 2021, 21, 453-454.	4.6	0
4	Dynamics of antimicrobial resistance of Streptococcus pneumoniae following PCV10 introduction in Brazil: Nationwide surveillance from 2007 to 2019. Vaccine, 2021, 39, 3207-3215.	1.7	20
5	Genomic surveillance of Neisseria meningitidis serogroup B invasive strains: Diversity of vaccine antigen types, Brazil, 2016-2018. PLoS ONE, 2020, 15, e0243375.	1.1	2
6	Nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in a Brazilian elderly cohort. PLoS ONE, 2019, 14, e0221525.	1.1	14
7	Long-term effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae in children in Brazil. Vaccine, 2019, 37, 5357-5363.	1.7	27
8	Distribution of invasive Streptococcus pneumoniae serotypes before and 5†years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil. Vaccine, 2018, 36, 2559-2566.	1.7	61
9	Single-dose varicella vaccine effectiveness in Brazil: A case-control study. Vaccine, 2018, 36, 479-483.	1.7	19
10	Combined effect of PCV10 and meningococcal C conjugate vaccination on meningitis mortality among children under five years of age in Brazil. Human Vaccines and Immunotherapeutics, 2018, 14, 1138-1145.	1.4	7
11	Expansion of the multidrug-resistant clonal complex 320 among invasive Streptococcus pneumoniae serotype 19A after the introduction of a ten-valent pneumococcal conjugate vaccine in Brazil. PLoS ONE, 2018, 13, e0208211.	1.1	49
12	Increased risk of death and readmission after hospital discharge of critically ill patients in a developing country: a retrospective multicenter cohort study. Intensive Care Medicine, 2018, 44, 1090-1096.	3.9	9
13	Timeliness and risk factors associated with delay for pneumococcal conjugate 10-valent routine immunization in Brazilian children. Vaccine, 2017, 35, 1030-1036.	1.7	10
14	Impact of meningococcal C conjugate vaccination four years after introduction of routine childhood immunization in Brazil. Vaccine, 2017, 35, 2025-2033.	1.7	30
15	Reduction in all-cause otitis media-related outpatient visits in children after PCV10 introduction in Brazil. PLoS ONE, 2017, 12, e0179222.	1.1	22
16	Direct and indirect impact of 10-valent pneumococcal conjugate vaccine introduction on pneumonia hospitalizations and economic burden in all age-groups in Brazil: A time-series analysis. PLoS ONE, 2017, 12, e0184204.	1.1	39
17	Cost of management of severe pneumonia in young children: systematic analysis. Journal of Global Health, 2016, 6, 010408.	1.2	65
18	Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in São Paulo, Brazil. Vaccine, 2016, 34, 5604-5611.	1.7	78

#	Article	IF	CITATIONS
19	Evaluating the impact of PCV-10 on invasive pneumococcal disease in Brazil: A time-series analysis. Human Vaccines and Immunotherapeutics, 2016, 12, 285-292.	1.4	56
20	Early impact of 10-valent pneumococcal conjugate vaccine in childhood pneumonia hospitalizations using primary data from an active population-based surveillance. Vaccine, 2016, 34, 663-670.	1.7	37
21	Evaluation of Haemophilus influenzaetype b carrier status among children 10 years after the introduction of Hib vaccine in Brazil. Memorias Do Instituto Oswaldo Cruz, 2015, 110, 755-759.	0.8	11
22	Vaccination Coverage and Compliance with Three Recommended Schedules of 10-Valent Pneumococcal Conjugate Vaccine during the First Year of Its Introduction in Brazil: A Cross-Sectional Study. PLoS ONE, 2015, 10, e0128656.	1.1	12
23	Methicillin-resistant Staphylococcus aureus nasal carriage in neonates and children attending a pediatric outpatient clinics in Brazil. Brazilian Journal of Infectious Diseases, 2014, 18, 42-47.	0.3	14
24	Direct Effect of 10-Valent Conjugate Pneumococcal Vaccination on Pneumococcal Carriage in Children Brazil. PLoS ONE, 2014, 9, e98128.	1.1	35
25	Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. Lancet, The, 2013, 381, 1380-1390.	6.3	584
26	Effect of 10-Valent Pneumococcal Vaccine on Pneumonia among Children, Brazil. Emerging Infectious Diseases, 2013, 19, 589-597.	2.0	109
27	Bacteriology of Community-acquired Invasive Disease Found in a Multicountry Prospective, Population-based, Epidemiological Surveillance for Pneumococcus in Children in Latin America. Pediatric Infectious Disease Journal, 2012, 31, 1312-1314.	1.1	3
28	Population-based surveillance for invasive pneumococcal disease and pneumonia in infants and young children in Goiânia, Brazil. Vaccine, 2012, 30, 1901-1909.	1.7	30
29	Pneumococcal disease manifestation in children before and after vaccination: What's new?. Vaccine, 2011, 29, C2-C14.	1.7	20
30	Serotype and genotype distributions of pneumococcal carriage isolates recovered from Brazilian children attending day-care centres. Journal of Medical Microbiology, 2011, 60, 1455-1459.	0.7	9
31	Molecular assessment of invasive Streptococcus pneumoniae serotype 1 in Brazil: evidence of clonal replacement. Journal of Medical Microbiology, 2008, 57, 839-844.	0.7	15
32	Antimicrobial Resistance and Serotypes of Nasopharyngeal Strains ofStreptococcus pneumoniaein Brazilian Adolescents. Microbial Drug Resistance, 2006, 12, 29-32.	0.9	4